No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TBPH Theravance Biopharma
- 8.480
- -0.100-1.17%
Close Jun 14 16:00 ET
- 8.480
- 0.0000.00%
Post 16:07 ET
412.41MMarket Cap-9528P/E (TTM)
8.750High8.370Low301.75KVolume8.540Open8.580Pre Close2.55MTurnover1.56%Turnover RatioLossP/E (Static)48.63MShares11.71052wk High2.01P/B163.98MFloat Cap8.13052wk Low--Dividend TTM19.34MShs Float124.866Historical High--Div YieldTTM4.43%Amplitude6.100Historical Low8.460Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.Shares of Mama's Creations Inc (NASDAQ:MAMA) fell in today's pre-market trading following fi
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference tak
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
TD Cowen Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $10
TD Cowen analyst Marc Frahm maintains $Theravance Biopharma(TBPH.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 47.0% and
Theravance Biopharma (TBPH) Receives a Hold From TD Cowen
BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21
BTIG analyst Julian Harrison maintains $Theravance Biopharma(TBPH.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 49.4% and
Comments
Analysts show high confidence in Theravance Biopharma's growth rate, predicting a breakeven point by 2026. The company's lack of debt, which is unusual for a loss-making pharma, reduces the risk around investing in the company.
Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To ProfitTheravance Biopharma's high P/S ratio is alarming considering its unimpressive revenue predictions. Investors seem hopeful for a business turnaround, but analysts lack confidence. The anticipated revenue growth could pressure the share price.
The appointment of Jeremy Grant and the cooperation with Irenic are seen as positive steps towards strengthening Theravance's position. Irenic supports Theravance's potential to successfully complete the Phase 3 trial of ampreloxetine and deliver enhanced value to shareholders.
$Theravance Biopharma(TBPH.US$ Viatris And Theravance Biopharma Announce Top-Line Results From Yupelri Phase III Trial In China For The Treatment Of Chronic Obstructive Pulmonary Disease
Moomoo 24/7· 3 mins ago
Moomoo 24/7· 3 mins ago
The consensus remains at US$14.50 despite weaker earnings forecast, suggesting a belief in a minimal long-term impact to valuation. Yet, the rise in anticipated losses next year and reduced revenue predictions might raise investor concerns about Theravance Biopharma.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg